National Center for Complementary and Integrative Health (NCCIH)
NIH…Turning Discovery Into Health

Información en Español

Health Topics A-Z

NCCIH Research Blog

NCCIH Research Blog

NCCIH blogs about research developments related to complementary health practices. Check in regularly to keep up with the latest findings.

David Shurtleff, Ph.D.
David Shurtleff, Ph.D.
May 10, 2019

People have used marijuana, also called cannabis, for health purposes for thousands of years. Recent growing interest on the part of health-care providers and the public has been pointing toward use of cannabis and its components to treat medical conditions. A number of states and the District of Columbia have legislation allowing specific uses for medical purposes. At the same time, cannabis is Federally regulated as a Schedule I controlled substance. This situation presents unique obstacles for conducting basic and clinical research and for medication development. While research can be done, the landscape is complex and challenging. 

To help provide a path forward for addressing regulatory challenges in conducting research, NCCIH sponsored a workshop in December 2018 on “Evaluating the Therapeutic Potential of Cannabinoids: How To Conduct Research Within the Current Regulatory Framework.” We have just published the summary. The experts who presented at the workshop and reviewed its summary included researchers, government officials (from NCCIH, other NIH institutes, the Food and Drug Administration (FDA), and the Drug Enforcement Administration), and industry representatives. They discussed topics such as the state of the science on the risks and potential benefits of cannabis; the regulatory landscape; the FDA approval process; and how to advance the research, including toward FDA-approved product development for clinical use. 

At the workshop, participants acknowledged that the marketing and use of cannabis is running way ahead of the evidence. Because of that, health care providers face a dilemma of sharing recommendations with patients about cannabis when there is a dearth of evidence, publications, and/or high-quality studies. Also, the risk of adverse outcomes increases with self-administration of products that have few requirements for standardization or quality control.  

As I have blogged before, NCCIH supports studies on cannabinoids within the existing regulatory framework to expand the evidence base on their efficacy and safety. We see possible therapeutic benefit in some of the 80-plus phytocannabinoids and terpenes found in the cannabis plant.  NCCIH has issued several funding opportunity announcements (FOAs) highlighting our interests, including:

  • For mechanistic research on minor cannabinoids and terpenes from the cannabis plant in relation to pain and nociception (RFA-AT-19-008 and RFA-AT-19-009, which had a receipt date of March 16, 2019)
  • To support early-phase clinical trials of natural products and the development/characterization of their biological signaturesthe objective measures of a natural product’s effects (PAR-18-129 and PAR-18-128, still-active FOAs with fall 2019 receipt dates)
  • PA-18-917, to support projects examining the therapeutic potential of cannabinoids and the endocannabinoid system across a variety of pain conditions (an FOA co-sponsored by NCCIH with five other NIH components and with standard due dates). 

NCCIH is committed to requiring product integrity in studies of cannabis and other natural products. Our Product Integrity Policy helps raise investigators’ and the Center’s confidence that an NCCIH-funded study will have definitive, reproducible results.

It was evident at the workshop that this field of research holds exciting potential. NCCIH shares the widespread hope of finding effective, safe options to control pain and address other difficult medical problems, including through rigorous studies on natural products such as cannabis.

  • View summary of “Evaluating the Therapeutic Potential of Cannabinoids: How To Conduct Research Within the Current Regulatory Framework” 
Partap S. Khalsa, D.C., Ph.D.
May 07, 2019
Partap S. Khalsa, D.C., Ph.D.

Upcoming National Advisory Council for Complementary and Integrative Health (NACCIH) meeting on Friday, June 7, 2019. Hear about our activities, policies, and funding priorities.

Read more

Lanay M. Mudd, Ph.D.
April 24, 2019
Lanay Mudd, Ph.D.

In this blog post, Dr. Lanay Mudd discusses different Career Development Mechanisms, or K awards, and selecting the right funding opportunity announcement (FOA) to fit your science.

Read more

Emmeline Edwards, Ph.D.
March 18, 2019
Emmeline Edwards, Ph.D.

In this blog post Dr. Emmeline Edwards discusses planned NCCIH activities around the 2019 American Pain Society Scientific Meeting In Milwaukee, WI between April 3 & April 6, 2019.

Read more

March 05, 2019
NCCIH Blog Team

This blog post announces NCCIH’s Integrative Medicine Research Lecture Series. Dr. Sean Brady kicks it off on March 14, 2019, at 11:00 a.m. with a talk on “Microbes in Our Gut: Emerging Insights on Health and Disease” on the NIH campus in Bethesda, MD. Other speakers follow May 9 and June 10.

Read more

Wen G. Chen, Ph.D.
March 04, 2019
Wen Chen, Ph.D.

In this blog post, Dr. Wen Chen invites readers to attend the inaugural NIH workshop on “The Science of Interoception and Its Roles in Nervous System Disorders” on April 16 and 17, 2019, on the NIH Campus in Bethesda, Maryland.

Read more

This page last modified March 20, 2019